• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《荷兰医疗保健成本研究手册》更新版

Update of the Dutch manual for costing studies in health care.

作者信息

Kanters Tim A, Bouwmans Clazien A M, van der Linden Naomi, Tan Siok Swan, Hakkaart-van Roijen Leona

机构信息

Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.

Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia.

出版信息

PLoS One. 2017 Nov 9;12(11):e0187477. doi: 10.1371/journal.pone.0187477. eCollection 2017.

DOI:10.1371/journal.pone.0187477
PMID:29121647
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5679627/
Abstract

OBJECTIVES

Dutch health economic guidelines include a costing manual, which describes preferred research methodology for costing studies and reference prices to ensure high quality studies and comparability between study outcomes. This paper describes the most important revisions of the costing manual compared to the previous version.

METHODS

An online survey was sent out to potential users of the costing manual to identify topics for improvement. The costing manual was aligned with contemporary health economic guidelines. All methodology sections and parameter values needed for costing studies, particularly reference prices, were updated. An expert panel of health economists was consulted several times during the review process. The revised manual was reviewed by two members of the expert panel and by reviewers of the Dutch Health Care Institute.

RESULTS

The majority of survey respondents was satisfied with content and usability of the existing costing manual. Respondents recommended updating reference prices and adding some particular commonly needed reference prices. Costs categories were adjusted to the international standard: 1) costs within the health care sector; 2) patient and family costs; and 3) costs in other sectors. Reference prices were updated to reflect 2014 values. The methodology chapter was rewritten to match the requirements of the costing manual and preferences of the users. Reference prices for nursing days of specific wards, for diagnostic procedures and nurse practitioners were added.

CONCLUSIONS

The usability of the costing manual was increased and parameter values were updated. The costing manual became integrated in the new health economic guidelines.

摘要

目标

荷兰卫生经济指南包括一本成本核算手册,该手册描述了成本核算研究的首选研究方法和参考价格,以确保高质量的研究以及研究结果之间的可比性。本文描述了成本核算手册与上一版本相比最重要的修订内容。

方法

向成本核算手册的潜在用户发送了一份在线调查问卷,以确定需要改进的主题。成本核算手册与当代卫生经济指南保持一致。对成本核算研究所需的所有方法部分和参数值,特别是参考价格进行了更新。在审查过程中多次咨询了卫生经济学家专家小组。修订后的手册由专家小组的两名成员以及荷兰医疗保健研究所的审查人员进行了审核。

结果

大多数调查受访者对现有成本核算手册的内容和可用性感到满意。受访者建议更新参考价格并添加一些特别常用的参考价格。成本类别已调整为国际标准:1)医疗保健部门内的成本;2)患者及家庭成本;3)其他部门的成本。参考价格已更新以反映2014年的数值。方法章节进行了重写,以符合成本核算手册的要求和用户的偏好。增加了特定病房护理天数、诊断程序和执业护士的参考价格。

结论

成本核算手册的可用性得到了提高,参数值也进行了更新。成本核算手册已融入新的卫生经济指南中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a54/5679627/b40c3d96f2f2/pone.0187477.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a54/5679627/b40c3d96f2f2/pone.0187477.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a54/5679627/b40c3d96f2f2/pone.0187477.g001.jpg

相似文献

1
Update of the Dutch manual for costing studies in health care.《荷兰医疗保健成本研究手册》更新版
PLoS One. 2017 Nov 9;12(11):e0187477. doi: 10.1371/journal.pone.0187477. eCollection 2017.
2
Standardisation of costs: the Dutch Manual for Costing in economic evaluations.成本标准化:荷兰经济评估成本核算手册
Pharmacoeconomics. 2002;20(7):443-54. doi: 10.2165/00019053-200220070-00002.
3
Update of the Dutch Manual for Costing in Economic Evaluations.荷兰成本效益分析手册更新版。
Int J Technol Assess Health Care. 2012 Apr;28(2):152-8. doi: 10.1017/S0266462312000062.
4
Emergent Challenges in Determining Costs for Economic Evaluations.经济评估中成本确定的新挑战
Pharmacoeconomics. 2017 Feb;35(2):129-139. doi: 10.1007/s40273-016-0465-1.
5
Valuing inter-sectoral costs and benefits of interventions in the healthcare sector: methods for obtaining unit prices.评估医疗保健部门干预措施的部门间成本和效益:获取单位价格的方法。
Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):77-84. doi: 10.1586/14737167.2016.1141679. Epub 2016 Feb 12.
6
Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.预算影响分析——良好实践原则:ISPOR 2012 预算影响分析良好实践 II 工作组报告。
Value Health. 2014 Jan-Feb;17(1):5-14. doi: 10.1016/j.jval.2013.08.2291. Epub 2013 Dec 13.
7
[Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation].[德国卫生经济评价的经验性标准成本——卫生经济评价方法工作组的一项提议]
Gesundheitswesen. 2005 Oct;67(10):736-46. doi: 10.1055/s-2005-858698.
8
Side-effects of antiepileptic drugs: the economic burden.抗癫痫药物的副作用:经济负担
Seizure. 2014 Mar;23(3):184-90. doi: 10.1016/j.seizure.2013.11.009. Epub 2013 Nov 21.
9
Evidence-based clinical guidelines in Kyrgyz Republic.吉尔吉斯共和国基于证据的临床指南。
Int J Risk Saf Med. 2015;27 Suppl 1:S45-6. doi: 10.3233/JRS-150683.
10
Process evaluation of health system costing - Experience from CHSI study in India.卫生系统成本核算的过程评价——印度 CHSI 研究的经验。
PLoS One. 2020 May 13;15(5):e0232873. doi: 10.1371/journal.pone.0232873. eCollection 2020.

引用本文的文献

1
Specialized orthotic care to improve functioning in adults with neuromuscular disorders: results of an open-label blinded end-point randomized controlled trial.专业矫形护理改善神经肌肉疾病成人患者的功能:一项开放标签盲终点随机对照试验的结果
Eur J Phys Rehabil Med. 2025 Jun;61(3):496-508. doi: 10.23736/S1973-9087.25.08770-2.
2
Cost-Effectiveness of Ultra-Early Tranexamic Acid as Add-On to Standard Care After Subarachnoid Hemorrhage (ULTRA Trial).蛛网膜下腔出血后超早期氨甲环酸作为标准治疗补充用药的成本效益(ULTRA试验)
Eur J Neurol. 2025 Aug;32(8):e70208. doi: 10.1111/ene.70208.
3
Hotspotters Project: a study protocol for a stepped wedge cluster RCT on the cost-effectiveness of 12-month proactive, integrated and personalised care for patients with problems on multiple life domains and high acute care use.

本文引用的文献

1
From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.从良好到更佳:荷兰医疗保健经济评估新指南
Pharmacoeconomics. 2016 Nov;34(11):1071-1074. doi: 10.1007/s40273-016-0431-y.
2
Standard Costs for Health Economic Evaluations: An International Comparison.卫生经济评估的标准成本:一项国际比较
Value Health. 2014 Nov;17(7):A427. doi: 10.1016/j.jval.2014.08.1074. Epub 2014 Oct 26.
3
The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses.
热点人群项目:一项阶梯楔形整群随机对照试验的研究方案,该试验旨在探究针对多个生活领域存在问题且急性护理使用率高的患者,提供为期12个月的主动、综合和个性化护理的成本效益。
BMJ Open. 2025 Aug 10;15(8):e087940. doi: 10.1136/bmjopen-2024-087940.
4
The Economic and societal burden associated with drug-resistant epilepsy in the Netherlands: an AIM@EPILEPSY burden-of-disease study protocol.荷兰耐药性癫痫相关的经济和社会负担:一项“癫痫防治行动”疾病负担研究方案
BMJ Open. 2025 Jul 25;15(7):e095123. doi: 10.1136/bmjopen-2024-095123.
5
Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands.恩格列净在荷兰慢性心力衰竭患者中的成本效益,无论左心室射血分数如何
Am J Cardiovasc Drugs. 2025 Jul 12. doi: 10.1007/s40256-025-00749-6.
6
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.帕博利珠单抗单药治疗高程序性死亡配体1表达的晚期或转移性非小细胞肺癌的成本效益取决于长期存活者。
Clin Drug Investig. 2025 Jul 9. doi: 10.1007/s40261-025-01456-5.
7
Utility, Costs and Cost-Utility of Amyloid-PET in the Diagnostic Process of Memory Clinic Patients: A Trial-Based Economic Evaluation From AMYPAD-DPMS.淀粉样蛋白正电子发射断层扫描在记忆门诊患者诊断过程中的效用、成本及成本效用分析:来自AMYPAD-DPMS的基于试验的经济学评估
Eur J Neurol. 2025 Jun;32(6):e70197. doi: 10.1111/ene.70197.
8
Exploratory health economic analyses to support decisions within the innovation process in radiotherapy: Magnetic Resonance Linear Accelerator as a case study.支持放射治疗创新过程中决策的探索性卫生经济分析:以磁共振直线加速器为例
Tech Innov Patient Support Radiat Oncol. 2025 May 14;34:100314. doi: 10.1016/j.tipsro.2025.100314. eCollection 2025 Jun.
9
Cost-effectiveness of dialectical behavioural therapy versus treatment as usual for autism with suicidal behaviours: single-blind randomised controlled trial.辩证行为疗法与常规治疗对伴有自杀行为的自闭症患者的成本效益:单盲随机对照试验。
Eur J Health Econ. 2025 May 31. doi: 10.1007/s10198-025-01794-3.
10
Study protocol for a multicentre randomised controlled trial using music prehabilitation to reduce preoperative anxiety before oncological colorectal surgery: the MU-PRIOR trial.一项多中心随机对照试验的研究方案:采用音乐预康复降低肿瘤性结直肠手术术前焦虑——MU-PRIOR试验
BMJ Open. 2025 Apr 29;15(4):e095239. doi: 10.1136/bmjopen-2024-095239.
iMTA生产力成本问卷:一种用于测量和评估与健康相关的生产力损失的标准化工具。
Value Health. 2015 Sep;18(6):753-8. doi: 10.1016/j.jval.2015.05.009. Epub 2015 Aug 20.
4
Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies.在经济评估中纳入非正式护理重要吗?对成本效益研究中非正式护理的纳入情况及其影响的系统评价。
Pharmacoeconomics. 2015 Feb;33(2):123-35. doi: 10.1007/s40273-014-0218-y.
5
How to include informal care in economic evaluations.如何将非正规护理纳入经济评价。
Pharmacoeconomics. 2013 Dec;31(12):1105-19. doi: 10.1007/s40273-013-0104-z.
6
Economic evaluations in European reimbursement submission guidelines: current status and comparisons.欧洲报销提交指南中的经济评估:现状与比较。
Expert Rev Pharmacoecon Outcomes Res. 2013 Oct;13(5):579-95. doi: 10.1586/14737167.2013.837766.
7
Update of the Dutch Manual for Costing in Economic Evaluations.荷兰成本效益分析手册更新版。
Int J Technol Assess Health Care. 2012 Apr;28(2):152-8. doi: 10.1017/S0266462312000062.
8
Standardizing the inclusion of indirect medical costs in economic evaluations.标准化经济评估中间接医疗成本的纳入。
Pharmacoeconomics. 2011 Mar;29(3):175-87. doi: 10.2165/11586130-000000000-00000.
9
The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines.在司法管辖区之间转移评估损失生产力的价值。国家药物经济学指南之间的差异。
Value Health. 2010 Aug;13(5):519-27. doi: 10.1111/j.1524-4733.2010.00699.x.
10
What do international pharmacoeconomic guidelines say about economic data transferability?国际药物经济学指南对经济数据的可转移性有何说法?
Value Health. 2010 Dec;13(8):1028-37. doi: 10.1111/j.1524-4733.2010.00771.x.